The use of anti-CXCR4 drugs can also potentiate the anti-tumor activity of several targeted drugs, such as tyrosine kinase inhibitor or anti-PD-1 and anti-CTLA4 antibodies [25–28]. The gene discussed is CXCR4; the disease is neoplasm.